" class="no-js "lang="en-US"> AlloVir - Medtech Alert
Thursday, March 28, 2024
AlloVir | MTA

AlloVir

About AlloVir

AlloVir
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Related Story

AlloVir Appoints Derek Adams, Ph.D., to Board of Directors

February 24 2023

AlloVir, a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Derek […]